Profitability Metrics

Gross Margin
33.94%
Operating Margin
45.76%
Net Margin
26.06%

Efficiency Metrics

Revenue per Expense Ratio
1.18
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
38.88%
Income Tax Rate
18.27%
EPS
4.3000000000

Balance Sheet Analysis

Current Ratio
1.51
Cash Ratio
0.50
Working Capital
$20.75B
Debt to Equity
2.16
Debt to Assets
15.57%
Equity Ratio
7.20%

Cash Flow Analysis

Operating Cash Flow Ratio
-10.43%
Free Cash Flow Ratio
-11.19%
CapEx to Revenue
0.76%
Dividends Paid
$615.03M
Stock Buybacks
$331.52M
Total Shareholder Returns
$946.55M
Cash Position Change
55.45%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 3.51%
  • Increased R&D investment by 100.00%

Detailed Growth Metrics

Core Performance

Revenue
150.35%
Net Income
464.65%
EPS
413.87%
Operating Income
360.77%

Operational Efficiency

R&D Expenses
100.00%
SG&A Expenses
15.63%
Operating Cash Flow
71.70%
Free Cash Flow
70.13%

Balance Sheet Health

Assets
14.51%
Debt
12.05%
Book Value per Share
-6.00%
Inventory
-100.00%

Shareholder Returns

Dividends per Share
3.51%
Shares Outstanding
15.74%

Long Term Trends

3Y Revenue/Share
119.63%
5Y Revenue/Share
254.29%
3Y Dividend/Share
12.76%
5Y Dividend/Share
2.47%